Neuropeptides in Glioblastoma: How Brain Tumor Signaling Hijacks the Nervous System
Review reveals how glioblastoma tumors exploit neuropeptide signaling pathways including NPY, substance P, and others to promote growth, invasion, and immune evasion.
Quick Facts
What This Study Found
Glioblastoma exploits neuropeptide signaling (NPY, substance P, others) for tumor growth, invasion, and immune evasion, revealing potential therapeutic targets.
Key Numbers
Not specified — broad review covering multiple neuropeptide families and their roles in GBM.
How They Did This
Comprehensive review of neuropeptide signaling roles in glioblastoma biology, including tumor growth, invasion, and immune microenvironment.
Why This Research Matters
Glioblastoma has a median survival of ~15 months with no cure. Targeting the neuropeptide pathways these tumors depend on could provide entirely new treatment approaches.
The Bigger Picture
The nervous system-cancer interaction is an emerging frontier. Glioblastoma is unique because it grows within the brain's neuropeptide-rich environment. Understanding how tumors co-opt these signals could lead to neuropeptide-based therapies that disrupt tumor growth from a completely new angle.
What This Study Doesn't Tell Us
Review of a complex field with most evidence preclinical. Targeting neuropeptide pathways in the brain is challenging due to their normal physiological roles.
Questions This Raises
- ?Could NPY receptor antagonists slow glioblastoma growth?
- ?Which neuropeptide pathway is the most druggable target in glioblastoma?
- ?Do neuropeptide levels in cerebrospinal fluid predict glioblastoma aggressiveness?
Trust & Context
- Key Stat:
- Brain tumors exploit NPY Glioblastoma hijacks neuropeptide signaling for growth and immune evasion — revealing potential new treatment targets
- Evidence Grade:
- Moderate evidence: comprehensive review of preclinical evidence identifying neuropeptide-tumor interactions.
- Study Age:
- Published in 2025. Captures the latest understanding of neuropeptide roles in glioblastoma.
- Original Title:
- Neuropeptide Signaling in Glioblastoma: A Comprehensive Review of the Current State and Future Direction.
- Published In:
- Neuromolecular medicine, 27(1), 27 (2025)
- Authors:
- Afridi, Shahid, Muzzammil, Mohd, Ali, Intezar, Shahi, Mehdi H
- Database ID:
- RPEP-09773
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How do brain tumors use neuropeptides?
Glioblastoma cells express receptors for neuropeptides like NPY and substance P. These tumor cells use the brain's own chemical signals to fuel their growth, spread through brain tissue, and hide from the immune system.
Could blocking neuropeptides treat brain cancer?
Potentially. If specific neuropeptide pathways are essential for glioblastoma survival, drugs that block these signals could slow tumor growth. Several neuropeptide receptor antagonists already exist and could be repurposed for testing.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09773APA
Afridi, Shahid; Muzzammil, Mohd; Ali, Intezar; Shahi, Mehdi H. (2025). Neuropeptide Signaling in Glioblastoma: A Comprehensive Review of the Current State and Future Direction.. Neuromolecular medicine, 27(1), 27. https://doi.org/10.1007/s12017-025-08849-x
MLA
Afridi, Shahid, et al. "Neuropeptide Signaling in Glioblastoma: A Comprehensive Review of the Current State and Future Direction.." Neuromolecular medicine, 2025. https://doi.org/10.1007/s12017-025-08849-x
RethinkPeptides
RethinkPeptides Research Database. "Neuropeptide Signaling in Glioblastoma: A Comprehensive Revi..." RPEP-09773. Retrieved from https://rethinkpeptides.com/research/afridi-2025-neuropeptide-signaling-in-glioblastoma
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.